Treatment of Wilson's Disease Presenting with Neurological Symptoms

This protocol addresses Wilson's disease in patients who present with neurological symptoms — a clinically distinct situation in which both therapy selection and the manner of introduction require particular care.

Clinical Scenario

Neurological manifestations are a recognised presentation of Wilson's disease. Guideline consensus supports the use of zinc or chelating agents in this setting, with the choice and titration approach shaped by the neurological context.

Treatment Approach

Treatment involves either zinc or a chelating agent. When a chelator is chosen, a carefully graduated 'start low, go slow' strategy — with progressive dose escalation — is specifically recommended to manage neurological risk in this setting.

The complete agent selection criteria, dosing schedule, escalation pathway, and monitoring parameters are available in the full structured regimen below.

Treatment Goals

Progressive disappearance or attenuation of neurological symptoms
Decrease or normalisation of the UWDRS score
Progressive vanishing of T2/FLAIR hypersignal on brain MRI
Disappearance of Kayser-Fleischer rings

Clinical neurological improvement typically unfolds over a time course of 1–3 years; response to chelators may be delayed.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jhep.2024.11.007

Either zinc or chelators should be used in patients with a neurological presentation (LoE 2, strong recommendation, consensus).
A 'start low, go slow' treatment regimen is recommended for chelators, especially in patients with a neurological presentation (LoE 3, strong recommendation, strong consensus).
Neurological response to chelators may be delayed and is defined by the progressive disappearance or attenuation of symptoms and the decrease or normalisation of the UWDRS score.
Brain MRI can be used to measure treatment response with a progressive vanishing and disappearance of T2/FLAIR hypersignal.

View source ↗